J&J’s Mark Graham on advancing nipocalimab as treatment for SLE
Mark Graham shares that the company plans to explore nipocalimab's potential in targeting disease-driving pathways in SLE.
Drug Development
Cellares and TScan to assess automated manufacturing of TSC-101 therapy
Pfizer receives EC approval for Hympavzi to treat haemophilia
Contineum’s MS drug falls short in Phase II trial
Neurocrine’s depression treatment misses main goal in Phase II study
China accounts for one-fifth of global drugs in development
Imunon’s Phase III-stage IL-12 gene therapy alters tumour microenvironment in ovarian cancer
Four drugs race for first bispecific ADC approval
